OA10198A - Stable copper(i) complexes and methods related thereto - Google Patents
Stable copper(i) complexes and methods related thereto Download PDFInfo
- Publication number
- OA10198A OA10198A OA60750A OA60750A OA10198A OA 10198 A OA10198 A OA 10198A OA 60750 A OA60750 A OA 60750A OA 60750 A OA60750 A OA 60750A OA 10198 A OA10198 A OA 10198A
- Authority
- OA
- OAPI
- Prior art keywords
- copper
- complex
- complexes
- stable
- bcds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7144093A | 1993-06-02 | 1993-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA10198A true OA10198A (en) | 1996-12-18 |
Family
ID=22101339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA60750A OA10198A (en) | 1993-06-02 | 1995-12-01 | Stable copper(i) complexes and methods related thereto |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0701439A1 (fr) |
JP (1) | JPH08511006A (fr) |
AU (1) | AU7051794A (fr) |
CA (1) | CA2163640A1 (fr) |
OA (1) | OA10198A (fr) |
TW (1) | TW239077B (fr) |
WO (1) | WO1994027594A2 (fr) |
ZA (1) | ZA943857B (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6562854B2 (en) | 1994-12-14 | 2003-05-13 | Axys Pharmaceuticals, Inc. | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders |
AU6274896A (en) * | 1995-06-06 | 1996-12-24 | Procyte Corporation | Stable copper(i) complexes as active therapeutic substances |
US5637311A (en) * | 1995-06-29 | 1997-06-10 | Procyte Corporation | Zinc(II) complexes and methods related thereto |
US7045531B1 (en) | 1997-03-11 | 2006-05-16 | The General Hospital Corporation | Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator |
US6150379A (en) * | 1997-11-26 | 2000-11-21 | Axys Pharmaceuticals, Inc. | Compounds and compositions as anticoagulants |
US6638711B1 (en) | 1999-04-29 | 2003-10-28 | The General Hospital Corporation | Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation |
WO2005115379A2 (fr) * | 2004-05-24 | 2005-12-08 | New York University | Methode de traitement ou de prevention d'effets pathologiques d'augmentations aigues de l'hyperglycemie et/ou d'augmentations aigues de flux d'acides gras libres |
NZ565003A (en) * | 2005-06-20 | 2011-11-25 | Dynamiclear Pty Ltd | Composition for treating skin lesions |
KR20110054035A (ko) * | 2008-09-03 | 2011-05-24 | 가부시키가이샤 엔비씨 메슈테크 | 항바이러스제 |
US10098857B2 (en) | 2008-10-10 | 2018-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds |
TWI580787B (zh) * | 2012-12-28 | 2017-05-01 | 簡宏堅 | 重組蛋白質、含有該重組蛋白質之醫藥組成物及該重組蛋白質之製備方法 |
WO2019055490A1 (fr) | 2017-09-14 | 2019-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | Conditionnement de tissu irradié pour rétention de greffe de graisse |
EP3810144A4 (fr) * | 2018-06-04 | 2022-08-17 | Chemistryrx | Compositions topiques pour stimuler la pousse des cheveux |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4760051A (en) * | 1985-01-24 | 1988-07-26 | Pickart Loren R | Use of GHL-Cu as a wound-healing and anti-inflammatory agent |
JPS6259213A (ja) * | 1985-09-10 | 1987-03-14 | Eisai Co Ltd | ス−パ−オキサイド除去剤 |
-
1993
- 1993-11-03 TW TW082109174A patent/TW239077B/zh active
-
1994
- 1994-06-02 CA CA002163640A patent/CA2163640A1/fr not_active Abandoned
- 1994-06-02 ZA ZA943857A patent/ZA943857B/xx unknown
- 1994-06-02 JP JP7501073A patent/JPH08511006A/ja active Pending
- 1994-06-02 AU AU70517/94A patent/AU7051794A/en not_active Abandoned
- 1994-06-02 EP EP94919342A patent/EP0701439A1/fr not_active Withdrawn
- 1994-06-02 WO PCT/US1994/006247 patent/WO1994027594A2/fr not_active Application Discontinuation
-
1995
- 1995-12-01 OA OA60750A patent/OA10198A/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW239077B (fr) | 1995-01-21 |
ZA943857B (en) | 1995-02-01 |
WO1994027594A2 (fr) | 1994-12-08 |
CA2163640A1 (fr) | 1994-12-08 |
JPH08511006A (ja) | 1996-11-19 |
EP0701439A1 (fr) | 1996-03-20 |
AU7051794A (en) | 1994-12-20 |
WO1994027594A3 (fr) | 1995-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Balzarini et al. | 9-(2-Phosphonylmethoxyethyl) adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys | |
OA10198A (en) | Stable copper(i) complexes and methods related thereto | |
De Clercq | The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection | |
Alizadeh et al. | Antiviral activities of pyridine fused and pyridine containing heterocycles, a review (from 2000 to 2020) | |
Touyz et al. | Reactive oxygen species in vascular biology: implications in hypertension | |
US9809616B2 (en) | Pyrimidine nucleosides and their monophosphate prodrugs for the treatment of viral infections and cancer | |
Meier et al. | cyclo Sal-Pronucleotides of 2 ‘-Fluoro-ara-and 2 ‘-Fluoro-ribo-2 ‘, 3 ‘-dideoxyadenosine as a Strategy to Bypass a Metabolic Blockade | |
Sharma et al. | Hypolipidemic, anti-inflammatory, and antineoplastic activity and cytotoxicity of flavonolignans isolated from Hydnocarpus wightiana seeds | |
MXPA01001893A (es) | Derivados de quinazolina. | |
AU4368799A (en) | Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases | |
JP2007532665A (ja) | Hivインテグラーゼ阻害剤化合物のホスホネート類似物 | |
US5637311A (en) | Zinc(II) complexes and methods related thereto | |
Al-Jafari et al. | Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: Phenserine | |
US6339073B1 (en) | Uses of nicotinamide adenine dinucleotide and its derivatives for treatment of malignant and infectious diseases | |
Sato et al. | Evidence of direct generation of oxygen free radicals from heterocyclic amines by NADPH/cytochrome P‐450 reductase in vitro | |
WO1996039144A1 (fr) | Complexes cuivreux stables utilises comme substances a activite therapeutique | |
Saraswathi et al. | Inhibition of glycolysis and respiration of sarcoma-180 cells by echitamine chloride | |
Sayre et al. | Dopaminergic neurotoxicity in vivo and inhibition of mitochondrial respiration in vitro by possible endogenous pyridinium‐like substances | |
Legrand-Poels et al. | HIV-1 promoter activation following an oxidative stress mediated by singlet oxygen | |
Hampton et al. | Evidence for the conformation of enzyme-bound adenosine 5'-phosphate. Substrate and inhibitor properties of 8, 5'-cycloadenosine 5'-phosphate with adenylate kinase, adenylate aminohydrolase, adenylosuccinate lyase, and 5'-nucleotidase | |
CHATTOPADHYAYA | The chemical synthesis and antiviral properties of an acyclovir-phospholipid conjugate | |
Zheng et al. | UNC5293, a potent, orally available and highly MERTK-selective inhibitor | |
Hamon et al. | Effect of antineoplastic and cytotoxic Mannich bases derived from conjugated styryl ketones on mitochondrial respiration in rat liver cells | |
Rosowsky et al. | Synthesis and in vitro activity of long-chain 5 ‘-O-[(Alkoxycarbonyl) phosphinyl]-3 ‘-azido-3 ‘-deoxythymidines against wild-type and AZT-and foscarnet-resistant strains of HIV-1 | |
Tedde et al. | Effects of 2′-deoxycoformycin infusion on mouse adenosine deaminase |